Health
Alnylam Receives Positive Recommendation From Canada's Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (vutrisiran injection), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis
Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025, AMVUTTRA® was authorized by Health Canada for the treatment of cardiomyopathy in adult patients with wild-type or hereditary transthyretin-mediated amyloidosis (wtATTR or hATTR amyloidosis). This is an expanded indication for AMVUTTRA®, which was originally authorized for sale in Canada in 2023 for
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"MISSISSAUGA, ON, March 2, 2026 /CNW/ - Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025, AMVUTTRA® was authorized by Health Canada for the treatment of cardiomyopathy in adult patients with wild-type or hereditary transthyretin-mediated amyloidosis (wtATTR or hATTR amyloidosis). This is an expanded indication for AMVUTTRA®, which was originally authorized for sale in Canada in 2023 for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis.2","length":641,"tagName":"p"},{"type":"text","content":"Cardiomyopathy associated with wild-type or hereditary transthyretin amyloidosis (ATTR-CM) is a serious, progressive, and ultimately fatal disease.3,4 There is no cure for ATTR-CM, which is caused by misfolded transthyretin (TTR) fibrils (malformed proteins) that build up primarily in your heart and elsewhere in the body. This makes it harder for the heart to pump blood, which can cause irreversible damage, and lead to heart failure.5 Patients' life expectancy after diagnosis is currently two to five years, underscoring the critical need for early and accurate detection to slow disease progression.6","length":615,"tagName":"p"},{"type":"text","content":""This recommendation brings us one step closer to delivering access to a first‑in‑class treatment that has a fundamentally different mechanism of action, targeting the root cause of the disease, rather than simply managing the symptoms," says Colleen Coxson, Country General Manager, Alnylam Canada ULC. "AMVUTTRA® expands the treatment landscape, offering patients and physicians an important new option that helps preserve function, enhance quality of life, and support longer survival. Our hope is that patients will gain swift access to this much needed therapy, and we remain committed to collaborating with all relevant partners to help make this a reality."","length":684,"tagName":"p"},{"type":"text","content":"The positive recommendation for reimbursement was supported by the results of the HELIOS-B Phase 3 study, a randomized, double-blind, placebo-controlled, multicenter, global trial that enrolled adult patients with wtATTR or hATTR amyloidosis with cardiomyop...